Table 2.

Grade 3 or 4 adverse events (CTCAE v4.0) grouped by therapy arm, showing numbers and percentages of patients.

CTCAE term	ET (n = 184)		CDK4/6i (n = 141)
	n	%	n	%
Neutrophil count decreased	0	0	5	3.5
Anemia	0	0	3	2.1
Abdominal pain	0	0	1	0.7
Allergic reaction	1	0.5	0	0
Concentration impairment	1	0.5	0	0
Diarrhea	0	0	1	0.7
Dyspnea	0	0	1	0.7
Edema limbs	1	0.5	0	0
GGT increased	0	0	1	0.7
Insomnia	1	0.5	0	0
Lung infection	0	0	1	0.7
Lymphedema	1	0.5	0	0
Mucositis oral	0	0	1	0.7
Nail discoloration	0	0	1	0.7
Nausea	0	0	1	0.7
Non-cardiac chest pain	0	0	1	0.7
Pain	1	0.5	0	0
Renal and urinary disorders - Other, specify	1	0.5	0	0
Surgical and medical procedures - Other, specify	1	0.5	0	0
Transient ischemic attacks	0	0	1	0.7
Vomiting	0	0	1	0.7

CDK4/6i, CDK4/6 inhibitors; CTCAE, Common Terminology Criteria for Adverse Events; ET, endocrine therapy.